Molecular Probes of Mismatched DNA

LSCCB
Overview

Luminescent platinum compounds that specifically interact mismatched DNA with potential for cancer analysis

  • Molecular Probes of Mismatched DNA 0
Commercialisation opportunities
LSCCB, HKU and start-up company GoldPorp Pharma Ltd are developing the proprietary anticancer metal compounds with possibility of collaborative research projects and licensing.
Problem addressed

DNA mismatch occurs in many types of cancer due to impaired mismatch repair capacity. Molecular probes that selectively bind to mismatched DNA for theranostic applications are sparse.

Innovation
  • Luminescent platinum compounds that specifically recogize DNA mismatches showing dramatic turn-on emission enhancement or colour changes upon binding to the mismatched sites
Key impact
  • The luminescent probes that detect DNA mismatch in cancer cells will have significant impact on research on the DNA mismatch and the repair mechanism.
Application
  • Molecular probes of DNA mismatch may be potential theranostic agents for mismatch repair deficient cancer.

Patent

  • US10,378,046
  • ZL201680048649.8
  • EP3310790

Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of  HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.

Enquiry
Related Innovations